Fiche publication
Date publication
septembre 2026
Journal
Neurology(R) neuroimmunology & neuroinflammation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Pittock SJ, Barnett MH, Bennett JL, Berthele A, de Sèze J, Levy M, Nakashima I, Oreja-Guevara C, Palace J, Paul F, Pozzilli C, Pathak R, Allen K, Parks B, Kim HJ
Lien Pubmed
Résumé
Ravulizumab, a complement component 5 inhibitor, was approved for the treatment of adults with anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) based on results of the primary treatment period (PTP) of CHAMPION-NMOSD, a phase 3, open-label, external placebo-controlled trial. Here, we report the final efficacy and safety results of CHAMPION-NMOSD (PTP and the long-term extension [LTE]).
Mots clés
Humans, Neuromyelitis Optica, drug therapy, Female, Aquaporin 4, immunology, Adult, Middle Aged, Antibodies, Monoclonal, Humanized, adverse effects, Male, Autoantibodies, blood, Complement Inactivating Agents, pharmacology, Outcome Assessment, Health Care
Référence
Neurol Neuroimmunol Neuroinflamm. 2026 09;13(5):e200609
